Asia Fresh News

Asia Fresh Stories

Archive for December 10th, 2013

Heraeus Increases PV Paste Production Capacity at its Singapore Site

leave a comment »

Heraeus continues its commitment to the PV Industry

SINGAPORE, Dec. 9, 2013 /PRNewswire/ — Heraeus’ Photovoltaics Business Unit is increasing their production capacity at its site in Singapore. As Pete Horan, Vice President Operations, points out, “ever since we built our Singapore factory we have seen increasing concentration of our customer base in Asia. I expect our paste production volume in Singapore to increase significantly over the next years.”

Heraeus will continue production at its site in West Conshohocken, Pennsylvania, where it had recently enhanced its R&D capabilities. In parallel, the site in Hanau, Germany will concentrate on Technical Service and Applications. Andreas Liebheit, Senior Vice President managing the Photovoltaics Business Unit adds: “Bringing even more of our Production Capacity close to our prominent Asian partners, our Singapore site will become even more important in the future. Being able to meet increasing demand at reasonable lead times is the key to success in the fast moving PV industry. Moreover this South-East Asian operation provides a perfect environment for continuous improvements in lean management throughout the entire supply chain and manufacturing process.”

Increasing production capacity at its Singapore site underlines Heraeus’ continued strong commitment to the PV market. Heraeus has been a technology leader in silver paste ever since it entered this industry in 2008.

About the Heraeus Photovoltaics Business Unit

The Heraeus Photovoltaics Business Unit is an industry leading developer and manufacturer of silver metallization pastes for the photovoltaic industry. For over 40 years, Heraeus has built a reputation of innovation, extensive research and new product development in thick film technologies for some of the most prominent companies within a variety of industries. In the field of photovoltaics, the Heraeus Photovoltaics Business Unit applies this history and its innovative technology to offer metallization pastes for solar cell applications. The Heraeus SOL Series of silver pastes is specially formulated to provide higher efficiencies and wider processing windows, resulting in better yields and higher output for cell manufacturers.

Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with more than 160 years of tradition. Our fields of competence include precious metals, materials and technologies, sensors, biomaterials and medical products, quartz glass, and specialty light sources. In the financial year 2012 Heraeus generated product revenues of EUR 4.2 billion and precious metal trading revenues of EUR 16 billion. With more than 12,200 employees in over 100 subsidiaries worldwide, Heraeus holds a leading position in its global markets.

http://www.pvsilverpaste.com
Source: Heraeus

Written by asiafreshnews

December 10, 2013 at 3:31 pm

Posted in Uncategorized

ABB in Singapore Opens New Service Center on Jurong Island

leave a comment »

New center will provide accessible support to customers on the industrial offshore island, focusing service growth ambitions
SINGAPORE, Dec. 10, 2013 /PRNewswire/ — ABB, the leading power and automation technology group, officially opens its Jurong Island Service Center today, as part of a strategic move to be closer to customers on the industrial island off the south-western coast of Singapore.
ABB’s regional service team is based in Singapore, along with several regional and global engineering centers.
ABB’s regional service team is based in Singapore, along with several regional and global engineering centers.
Service is one of ABB’s key focus areas, providing advanced and responsive support for a wide range of ABB products. This support includes engineering, consulting, modernization and maintenance services, as well as training for various ABB products.
“Service is a major growth area for ABB. Over the past 2 years, ABB has made significant investments in service around the world, primarily through investing in our people, as well as developing our offerings through R&D,” said Haider Rashid, country manager of ABB in Singapore. “This new service center is an important milestone for us, demonstrating our commitment to Singapore and to our customers here.”
“The service center reflects an increasing sophistication in our service offerings and brings us much closer to our customers, enabling us to better understand their evolving needs, and help them reap more value from their capital investments,” added Bertil Brandin, ABB’s head of service in Singapore. “The facility will provide fast and efficient response to customers around the clock and full access to ABB’s power and automation expertise.”
ABB recently won its first order for Service to be conducted through the new center. The order, worth S$1.3 million, includes products and services from across the ABB portfolio to a customer on Jurong Island.
The Service Center boasts over 150 square-meters of floor space, and includes a ground floor workshop and office space. It is also located in a convenient and accessible location that is in close proximity to the Jurong Island Highway.
ABB (http://www.abb.com) is a leader in power and automation technologies that enable utility and industry customers to improve performance while lowering environmental impact. The ABB Group of companies operates in around 100 countries and employs about 145,000 people.
ABB in the region has revenues of around US$3 billion and employs over 8,000 employees. In Singapore, it has revenues of around US$800 million and employs over 1,200 employees across 4 locations.
For help with any technical terms in this release, please go to: http://www.abb.com/glossary
For more information please contact:
ABB in Singapore Media Relations:
Piera Man; Timothy Fernandez
Singapore: Tel. +65-6776-5711
communications.sg@sg.abb.com
http://twitter.com/ABBcomms
Source: ABB
Related stocks: NYSE:ABB Swiss:ABBN

Written by asiafreshnews

December 10, 2013 at 12:02 pm

Posted in All releases

Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer

leave a comment »

– VTE patients with cancer treated with once-daily edoxaban had a numerically lower incidence of recurrent VTE and a 36% lower risk of clinically relevant bleeding compared to warfarin in a subgroup analysis of the phase 3 Hokusai-VTE study(1)
– In general, the annual incidence of VTE is as high as 20% in cancer patients and contributes to increased risk of mortality(2)
– Results in this subgroup analysis are consistent with the overall phase 3 Hokusai-VTE results previously reported(1,3)
– This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition
NEW ORLEANS and TOKYO, Dec. 9, 2013 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. Patients with either a history of cancer (n=563) or with active cancer (n=208) treated with the once-daily factor Xa-inhibitor edoxaban had a numerically lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared to warfarin (3.7% vs. 7.1%, respectively; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.28 to 1.00). Once-daily edoxaban also had a lower incidence of clinically relevant bleeding (major or non-major) compared to warfarin in cancer patients (12.4% vs. 18.8%, respectively; HR, 0.64; 95% CI, 0.45 to 0.92).(1) These findings are consistent with the results from the wider study population of 8,292 patients, which found once-daily edoxaban met the primary efficacy endpoint of non-inferiority for the treatment and prevention of VTE and superiority for the pre-specified principal safety outcome of clinically relevant bleeding compared to warfarin.(3) The data from this subgroup analysis of the phase 3 Hokusai-VTE study were presented at the 2013 American Society of Hematology Annual Meeting and Exposition in New Orleans.
“VTE is a common complication in cancer patients, and cancer patients with VTE are at higher risk of recurrence, so we are pleased that the subgroup analysis found that patients treated with edoxaban had a numerically lower incidence of VTE recurrence and clinically relevant bleeding compared to warfarin,” said Gary Raskob, PhD, Dean of the College of Public Health, Professor, Epidemiology and Medicine University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma and member of the Hokusai-VTE steering committee. “These findings provide us with insights about the potential benefit of edoxaban administered once-daily compared to warfarin for the treatment and prevention of recurrent symptomatic VTE in cancer patients.”
“VTE is a major cause of morbidity and mortality in patients with cancer, with an annual incidence that can be as high as 20% depending on the cancer type, background risk, and time since diagnosis,”(2,4) said Harry Buller, MD, PhD, Professor of Internal Medicine, Chairman of the Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands and Chairman of the Hokusai-VTE steering committee. “A promising finding was the sizeable reduction in recurrent symptomatic VTE among cancer patients who were treated with once-daily edoxaban.”
In the subset of 208 patients with active cancer, once-daily edoxaban had a rate of VTE recurrence of 3.7% compared to 7.1% for warfarin (HR, 0.55; 95% CI, 0.16 to 1.85) and an incidence of clinically relevant bleeding of 18.3% compared to 25.3% for warfarin (HR, 0.72; 95% CI, 0.40 to 1.30).(1)
“Our global Hokusai-VTE study of once-daily edoxaban included a broad range of patients and we recognize that VTE can be a common complication of cancer, so it´s not surprising to see that 9.3% of patients enrolled had active cancer or a history of cancer,” said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of Research and Development, Daiichi Sankyo Co., Ltd. and President and CEO of Daiichi Sankyo, Inc. in the United States. “Daiichi Sankyo is committed to help clinicians understand potential treatment strategies for diverse patient populations with VTE.”
About Hokusai-VTE
Hokusai-VTE was a global, event-driven, randomized, double-blind, parallel-group phase 3 clinical study involving 8,292 patients in 439 clinical sites across 37 countries to evaluate once-daily edoxaban in patients with either acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both. The Hokusai-VTE study was designed to reflect clinical practice using a flexible treatment duration of three to 12 months, including initial use of heparin, the proven global standard of care, in both arms, in a broad spectrum of VTE patients, including those with cancer.(3)
The full results were presented at the ESC Congress 2013 in Amsterdam and published in the New England Journal of Medicine, demonstrating that edoxaban met the primary efficacy endpoint of non-inferiority, with a numerically lower incidence of recurrent symptomatic VTE compared to warfarin (3.2% vs. 3.5%, respectively) (HR, 0.89; 95% CI, 0.70 to 1.13; p<0.001 for non-inferiority) following initial use of heparin in both arms. Recurrent symptomatic VTE was defined as the composite of recurrent symptomatic DVT, non-fatal symptomatic PE and fatal PE in patients during the 12-month study period. Once-daily edoxaban was also found to be superior to warfarin for the pre-specified principal safety outcome of clinically relevant bleeding (8.5% vs. 10.3%, respectively) (HR, 0.81; 95% CI, 0.71 to 0.94; p=0.004 for superiority) occurring during or within three days of interrupting or stopping study treatment.(3)
The Hokusai-VTE study included a prespecified subgroup analysis of patients with either a history of cancer (n=563) or with active cancer (n=208) if long term low molecular weight heparin (LMWH) was not planned due to availability, physician judgment or patient preference. The trial excluded patients with active cancer for whom long term treatment with LMWH was anticipated.(3)
The study is named after the famous Japanese artist and painter Katsushika Hokusai.
Venous Thromboembolism in Cancer Patients
VTE is an umbrella term for two conditions, DVT and PE. DVT is a blood clot found anywhere in the deep veins of the legs, while PE occurs when part of a clot detaches and lodges in the pulmonary arteries, causing a potentially fatal condition.(5)
In cancer patients, there is a significantly increased risk of VTE compared to the general population due to proteins released by malignant tumors that promote coagulation.(6) Studies have suggested that patients with cancers of the pancreas, lung, stomach and adenocarcinomas of unknown primary origin are at the highest risk of VTE due to the release of mucin, a protein commonly found in these types of cancers that can contribute to coagulation through the aggregation of platelets.(7,8) Certain anticancer therapies, such as chemotherapy, immunomodulatory agents and antiangiogenic agents also increase the risk of VTE in this patient population.(7)
In the general population VTE is a major cause of morbidity and mortality worldwide with an annual incidence of approximately one per 1,000 in developed countries, including an estimated 430,000 PE events, 680,000 DVT events and 540,000 deaths each year in the EU.(9,10) In the U.S., it is currently estimated that more than 950,000 VTE events and approximately 300,000 VTE related deaths occur each year.(11,12) In patients with cancer who develop VTE, there is a four- to eight-fold higher risk of dying after an acute thrombotic event than in patients without cancer.(7) Additionally, patients with cancer and VTE have a lower survival rate than those without VTE.(7)
About Edoxaban
Edoxaban is an investigational, oral, once-daily anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.(13) The global edoxaban clinical trial program includes two phase 3 clinical studies, Hokusai-VTE and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation). The results from these trials will form the basis of New Drug Applications for edoxaban for two potential indications, the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation, respectively.(3,14)
Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name Lixiana®. Elsewhere, including Europe and the U.S., edoxaban is currently in phase 3 clinical development and has not been approved in any indication.(15)
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: http://www.daiichisankyo.com.
Contact

Global Media US Media
Michaela Paudler-Debus, PhD Alyssa Dargento
Daiichi Sankyo Europe Daiichi Sankyo, Inc.
michaela.paudler-debus@daiichi-sankyo.eu adargento@dsi.com
+49-89-7808-685 (office) +1-973-944-2913 (office)
+49-176-11780966 (mobile) +1-973-727-1604 (mobile)
Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
References
(1) Raskob, GE et al. Edoxaban for long-term treatment Of venous thromboembolism in cancer patients. Presented at the 2013 American Society of Hematology Annual Meeting and Exposition. Abstract number 211.
(2) Ay, C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377-5382.
(3) Buller, H et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013.
(4) Lyman, GH et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology 2007;25:5490-5505.
(5) Van Beek, E et al. Deep vein thrombosis and pulmonary embolism. New York: John Wiley & Sons, 2009. Print.
(6) Boccaccio, C et al. Genetic link between cancer and thrombosis. J Clin Oncol 27:4827-4833.
(7) Lee, AYY, et al. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107:I-17-I-21.
(8) Wahrenbrock, M et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112:853–862 (2003).
(9) Bramlage P, Pittrow D, Kirch,W. Current concepts for the prevention of venous thromboembolism. Eur J Clin Invest 2005; 35 (Suppl. 1):4-11.
(10) Cohen A, Agnelli G, Anderson F. Venous thromboembolism (VTE) in Europe. Thromb Haemost 2007; 98: 756–764.
(11) Deitelzweig S, Lin J, Johnson BH, Schulman KL. Prevalence of venous thromboembolism in the USA: now and future. Thromb Haemost 2009;7 (Suppl. 2):207-8 (abstract OC-WE-018).
(12) Heit JA, Cohen AT, Anderson FAJ, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annual Meeting Abstracts. 106:910. 2005.
(13) Ogata, K et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
(14) Giugliano, RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013.
(15) Daiichi Sankyo press release – Daiichi Sankyo launches LIXIANA® (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopaedic surgery. 19 July 2011. Available at: http://www.daiichisankyo.com/news/detail/004123.html. [Last accessed: December 2013].
Source: Daiichi Sankyo

Written by asiafreshnews

December 10, 2013 at 11:34 am

Posted in All releases

IBS Employees Rally to Support Philippine Typhoon Victims

leave a comment »

SOLNA, Sweden, Dec. 9, 2013 /PRNewswire/ — Within four days of Super Typhoon Haiyan crashing the Philippine coast November 8, International Business Systems (IBS), a global leading integrated ERP and supply chain provider, had mobilized its workforce to raise money on behalf of storm victims.
(Logo: http://photos.prnewswire.com/prnh/20130731/CL46315LOGO)
Spearheaded by IBS Bookmaster Senior Business Consultant Rina Jacobson, a native of Lipa, Batangas in the Philippines, the IBS effort raised about $10,000 between November 13 and Thanksgiving Day (U.S.), November 28.
Jacobson launched the campaign through an email to IBS Chief Executive Officer Doug Braun, requesting permission to contact fellow employees. The IBS Leadership team agreed to match the first $2,500 collected, and a company-wide appeal was dispatched.
“We have a responsibility, not only as a company, but also as individuals to respond,” Braun said. “Our IBS family fans out into the world. The storm victims in the Philippines require our prayers and support.”
“I was in agony over the gravity of the situation as I watched the reports come in,” said Jacobson, who currently lives in Kelowna, British Columbia, with her husband Brad, also a senior business consultant with IBS Bookmaster.
“We reached our matching gift amounts in a matter of days,” Jacobson added. “I was overwhelmed by the response from the company and moved that so many people cared enough to help out.”
More than 40 donors across the company pitched in, representing IBS employees in the U.S., Canada, Australia, Sweden, Finland, United Kingdom, India, Netherlands, Denmark and Singapore. Monies raised were donated directly to various relief organizations, notably the Red Cross (www.redcross.org) and the Adventist Development and Relief Agency of Canada (www.adra.org), which organized relief on the ground in disaster areas alongside the United Nations Office for the Coordination of Humanitarian Affairs (OCHA), local and international partners and church organizations.
The typhoon, which was reported to be one of the strongest storms on record, left more than four-million people homeless and more than 4,000 dead, with rebuilding costs expected to exceed $18.7 billion (U.S.).
“Every dollar donated will go a long way to help the families affected by this disaster,” Jacobson said. “I am grateful for everyone at IBS for their spirit of generosity and support.”
About IBS
International Business Systems (IBS) is a leading global integrated ERP and supply chain distribution software solution provider. For more than 30 years, we have helped customers such as Galexis, Sigma, Rexel, Maxell, GE Lighting, Marangoni, WorldPac, MacFarlane Group, Scholastic Editions, Fidelitone, Totes Isotoner, Volvo, Goodyear, Skil, Oriola, Inotech and many more, streamline, automate and accelerate their distribution network processes, and drive profitability and efficiency.
For more information, please visit http://www.ibs.net.
Source: International Business Systems

Written by asiafreshnews

December 10, 2013 at 11:19 am

Posted in Uncategorized